The impact of CKD-MBD on cardiovascular disease

doi:10.3877/cma.j.issn.2095-3216.2020.01.008

Abstract

Abstract:

Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD). Traditional risk factors of cardiovascular disease can only partly account for the high frequency of cardiovascular disease in patients with CKD, while CKD-mineral and bone disorder (CKD-MBD) as a non-traditional risk factor may play a more essential role in this pathophysiological process. CKD-MBD is mainly characterized by disturbances of serum levels of calcium, phosphate, parathyroid hormone (PTH), active form of vitamin D, and fibroblast growth factor 23 (FGF23). Interventions for CKD-MBD may attenuate cardiovascular burdens and ameliorate mortality in CKD patients. This review summerized the latest researches in the impact of CKD-MBD on cardiovascular disease of CKD patients.

Key words: Chronic kidney disease-mineral and bone disorder, Cardiovascular diseases, Risk factor, Intervention

Weisheng Chen, Mengjing Wang, Minmin Zhang. The impact of CKD-MBD on cardiovascular disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(01): 38-42.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.01.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I01/38

References 41

[1]	Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. The Lancet, 2012, 379 (9818): 815-822.
[2]	Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2017 annual data report: epidemiology of kidney disease in the United States [J]. Am J Kidney Dis, 2018, 71 (3 Suppl 1): A7.
[3]	van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts [J]. Kidney Int, 2011, 79 (12): 1341-1352.
[4]	Gaita D, Mihaescu A, Schiller A. Of heart and kidney: a complicated love story [J]. Eur J Prev Cardiol, 2014, 21 (7): 840-846.
[5]	Weiner DE, Tighiouart H, Elsayed EF, et al. The Framingham predictive instrument in chronic kidney disease [J]. J Am Coll Cardiol, 2007, 50 (3): 217-224.
[6]	Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis [J]. JAMA, 2011, 305 (11): 1119-1127.
[7]	Seya K, Furukawa K, Chiyoya M, et al. 1-methyl-2-undecyl-4(1H)-quinolone, a derivative of quinolone alkaloid evocarpine, attenuates high phosphate-induced calcification of human aortic valve interstitial cells by inhibiting phosphate cotransporter PiT-1 [J]. J Pharmacol Sci, 2016, 131 (1): 51-57.
[8]	Wang M, Li H, You L, et al. Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients [J]. PLoS One, 2014, 9 (4): e93360.
[9]	Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease [J]. Kidney Int, 2013, 83 (5): 959-966.
[10]	Desjardins L, Liabeuf S, Renard C, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages [J]. Osteoporos Int, 2012, 23 (7): 2017-2025.
[11]	Xu H, Evans M, Gasparini A, et al. Outcomes associated to serum phosphate levels in patients with suspected acute coronary syndrome [J]. Int J Cardiol, 2017, 245: 20-26.
[12]	Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease [J]. Circulation, 2009, 119 (19): 2545-2552.
[13]	Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis [J]. J Am Soc Nephrol, 2011, 22 (10): 1913-1922.
[14]	Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy [J]. Cell Metab, 2015, 22 (6): 1020-1032.
[15]	Pastor-Arroyo EM, Gehring N, Krudewig C, et al. The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk [J]. Kidney Int, 2018, 94 (1): 49-59.
[16]	Robinson-Cohen C, Shlipak M, Sarnak M, et al. Impact of race on the association of mineral metabolism with heart failure: the Multi-Ethnic Study of Atherosclerosis [J]. J Clin Endocrinol Metab, 2020, 105(4): dgz218.
[17]	Marthi A, Donovan K, Haynes R, et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis [J]. J Am Soc Nephrol, 2018, 29 (7): 2015-2027.
[18]	Navarro-Garcia JA, Fernandez-Velasco M, Delgado C, et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: going beyond the confines of nephrology [J]. Eur J Clin Invest, 2018, 48 (4): 10.1111/eci.12902.
[19]	Chitalia N, Ismail T, Tooth L, et al. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients [J]. PLoS One, 2014, 9 (3): e91363.
[20]	Maiya S, Sullivan I, Allgrove J, et al. Hypocalcaemia and vitamin D deficiency: an important, but preventable, cause of life-threatening infant heart failure [J]. Heart, 2008, 94 (5): 581-584.
[21]	Li YC, Kong J, Wei M, et al. 1，25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system [J]. J Clin Invest, 2002, 110 (2): 229-238.
[22]	Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? [J]. QJM, 2002, 95 (12): 787-796.
[23]	Demer LL, Tintut Y. Interactive and multifactorial mechanisms of calcific vascular and valvular disease [J]. Trends Endocrinol Metab, 2019, 30 (9): 646-657.
[24]	Tentori F, Wang M, Bieber BA, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study [J]. Clin J Am Soc Nephrol, 2015, 10 (1): 98-109.
[25]	Lee SA, Lee MJ, Ryu GW, et al. Low serum intact parathyroid hormone level is an independent risk factor for overall mortality and major adverse cardiac and cerebrovascular events in incident dialysis patients [J]. Osteoporos Int, 2016, 27 (9): 2717-2726.
[26]	Chen T, Mao H, Chen C, et al. The role and mechanism of alpha-Klotho in the calcification of rat aortic vascular smooth muscle cells [J]. Biomed Res Int, 2015, 2015: 194362.
[27]	Xie J, Yoon J, An SW, et al. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate [J]. J Am Soc Nephrol, 2015, 26 (5): 1150-1160.
[28]	Seiler S, Rogacev KS, Roth HJ, et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4 [J]. Clin J Am Soc Nephrol, 2014, 9 (6): 1049-1058.
[29]	Lello S, Capozzi A, Scambia G. Osteoporosis and cardiovascular disease: an update [J]. Gynecol Endocrinol, 2015, 31 (8): 590-594.
[30]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [J]. Kidney Int Suppl (2011), 2017, 7 (1): 1-59.
[31]	Ruospo M, Palmer SC, Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) [J]. Cochrane Database Syst Rev, 2018, 8(8): CD006023.
[32]	Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease [J]. Clin J Am Soc Nephrol, 2010, 5 (3): 512-518.
[33]	Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism [J]. Kidney Int, 2005, 68 (4): 1793-1800.
[34]	EVOLVE Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis [J]. N Engl J Med, 2012, 367 (26): 2482-2494.
[35]	Komaba H, Taniguchi M, Wada A, et al. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism [J]. Kidney Int, 2015, 88 (2): 350-359.
[36]	Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients [J]. Kidney Int, 2008, 74 (8): 1070-1078.
[37]	Kumar V, Yadav AK, Lal A, et al. A randomized trial of vitamin D supplementation on vascular function in CKD [J]. J Am Soc Nephrol, 2017, 28 (10): 3100-3108.
[38]	Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial [J]. JAMA Cardiol, 2017, 2 (6): 608-616.
[39]	Kaur G, Singh J, Kumar J. Vitamin D and cardiovascular disease in chronic kidney disease [J]. Pediatr Nephrol, 2019, 34 (12): 2509-2522.
[40]	Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality [J]. J Clin Invest, 2012, 122 (7): 2543-2553.
[41]	Neyra JA, Hu MC. αKlotho and chronic kidney disease [J]. Vitam Horm, 2016, 101: 257-310.

Please choose a citation manager

Content to export